This stock is no longer traded. It was delisted on July 2, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Sangamo Therapeutics Inc. is a clinical-stage genomic medicine company focused on developing innovative therapies to treat serious diseases. Its primary purpose is to translate advanced genomic technologies into transformative medicines for patients with conditions such as Fabry disease, hemophilia A, and immune-mediated rejection in kidney transplantation. Key clinical-stage product candidates include ST-920, a gene therapy in Phase 1/2 for Fabry disease; TX200, a CAR-Treg therapy in Phase 1/2 for preventing rejection in HLA-A2 mismatched kidney transplants; and SB-525, a gene therapy in Phase 3 for moderately severe to severe hemophilia A. The company also advances preclinical programs targeting tauopathies, ALS/FTD, and Huntington's disease. Sangamo Therapeutics Inc. maintains strategic partnerships with leading biopharma companies like Pfizer, Novartis, and Sanofi to support its pipeline development. Operating in the genomic medicine sector, it plays a significant role in advancing gene therapy and cell therapy solutions for rare genetic disorders and neurological conditions in the United States.
Website501 Canal Blvd
Richmond, CA, 94804
United States
Summary of Jul 9's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Investors talking about SGMO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.